When Marcus, a 52-year-old financial advisor in Phoenix, pulled his week-4 labs, his IGF-1 had jumped from 112 ng/mL to 198 ng/mL. "My belly looked exactly the same," he told his prescriber. "I almost quit." He didn't. By week 20, his waist was down 2.3 inches, and his wife asked if he'd been dieting. He hadn't. That arc, the early biochemical proof followed by months of patience before anything shows in the mirror, is essentially the tesamorelin story for most patients.
Tesamorelin is a stabilized GHRH analog. The branded version (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Compounded tesamorelin is prescribed off-label by licensed pharmacies for broader use. Here's what the published trial data (primarily the Falutz Phase III trial) and clinical experience actually show about the timeline, broken into honest phases rather than marketing promises.
The First Month Is Boring (and That's Fine)
IGF-1 starts climbing within days of the first injection. By week 4, most patients show a substantial, lab-confirmed elevation. That's the earliest hard proof the peptide is doing its job.
What patients actually feel in those first four weeks is less exciting:
- Sleep may shift slightly (less dramatically than with sermorelin, for what it's worth)
- Some people get flushing or warmth after injecting
- Injection-site reactions happen
- Joint or muscle aches crop up in a subset of patients
- Occasional mild headaches
- Zero visible body composition change
Think of it like planting a garden. The seeds are germinating underground. You can't see anything yet, but something is happening. The side effects, when they show up, tend to peak in this window and then taper. If you're going to get achy joints or mild edema, this is when.
Weeks 4 Through 12: The Patience Tax
Between weeks 4 and 8, most of those early side effects resolve. Patients report better tolerance of the daily injection, sleep and recovery improvements, and resolution of the initial aches. But the mirror? Still not cooperating. Photos look basically the same.
Here's the thing: body composition is changing. It's just changing slowly and internally. Around week 8 to 12, the first subtle clues appear. A slight reduction in waist circumference. Pants fitting a little differently in the midsection. DEXA scans can pick up measurable shifts that your eyes can't. Lipid panels may start improving. But "subtle" is the operative word. If you're expecting a GLP-1-style dramatic transformation by week 10, tesamorelin will disappoint you.
Most prescribers pull labs at week 12: IGF-1 (ideally in the upper half of age-adjusted normal range), fasting glucose, HbA1c, possibly a lipid panel, blood pressure. Dose adjustments happen here if needed. Most patients on 2 mg daily stay there. Patients running above the normal IGF-1 range may get dialed back. Significant glucose elevation gets flagged for additional management.
Weeks 12 Through 26: Where It Gets Interesting
This stretch is typically where patient satisfaction climbs. The cumulative effect becomes visible, not just measurable:
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →- Waist circumference drops noticeably
- Body composition photos show real differences
- Other people start commenting
- Exercise capacity and recovery continue improving
- Lipid numbers keep trending in the right direction
Week 26, the six-month mark, is the benchmark. That's the pivotal trial endpoint. The documented visceral fat reduction at this point averages 15 to 18 percent on CT or MRI imaging. "Average" is doing heavy lifting in that sentence. Individual results range widely depending on baseline fat, age, insulin sensitivity, and lifestyle.
DEXA is a good proxy if CT/MRI isn't practical. Waist circumference is less precise but useful. Scale weight, somewhat counterintuitively, is the least useful metric. More on that below.
After Six Months: Maintenance and the Discontinuation Question
Past week 26, effects tend to plateau and hold with continued daily dosing. Visceral fat stays at the reduced level. IGF-1 stays elevated in the target range. Lipid improvements remain stable. Most patients continue at 2 mg with quarterly monitoring. Some prescribers consider a dose reduction if everything has stabilized nicely.
The less comfortable truth: stop tesamorelin, and visceral fat tends to creep back toward pre-treatment levels within months. The Egrifta trials documented this clearly. The reduction is not permanent.
What that means practically:
- If you have a defined goal (knock down visceral fat, reassess), a 6-to-12-month course is reasonable, with some expected regression after stopping
- If you want sustained body composition benefit, indefinite use with monitoring is the more common path
- Lifestyle factors (training, nutrition) significantly influence how much fat returns after discontinuation
What Tesamorelin Does Not Do
A few misconceptions worth clearing up because they come up constantly:
It won't move the scale much. Visceral fat shrinks while lean mass is preserved. Net weight change is often minimal. Patients who fixate on scale weight get frustrated for no good reason.
It's not an appetite suppressant. Unlike GLP-1 medications, tesamorelin has no direct effect on hunger or satiety signaling. You'll eat the same unless you deliberately change your diet.
It targets visceral fat, not subcutaneous fat. The belly fat you can pinch? Largely unchanged. The deeper fat wrapped around your organs? That's what's shrinking.
It doesn't build muscle without effort. Lean mass preservation is documented. Actual muscle gain requires a training stimulus. Sitting on the couch with elevated IGF-1 won't give you bigger shoulders.
Why Some People Respond Faster (or Slower)
Patient-to-patient variability is real and significant. The main drivers:
- Baseline visceral fat: More to lose means larger absolute changes.
- Baseline IGF-1: A more depleted GH axis produces a larger relative response.
- Age: Older patients sometimes respond more gradually, but typically just as effectively given enough time.
- Insulin sensitivity: Better insulin sensitivity correlates with better body composition outcomes.
- Training: Resistance training amplifies the lean mass preservation effect.
- Protein intake: Adequate protein supports lean mass; reasonable caloric intake supports recomposition.
- Consistency: This one matters more than people realize. Missed doses meaningfully blunt the cumulative response. Daily means daily.
If week 12 arrives with no IGF-1 response and no subjective improvement at all, it's time to troubleshoot: confirm reconstitution and injection technique, verify dosing consistency, check timing relative to meals, consider escalation from 1 mg to 2 mg if applicable, and evaluate whether comorbidities are interfering. True non-responders exist but are uncommon. Continuing unchanged past 12 weeks without any signal rarely produces a different outcome.
How to Actually Track Progress
The metrics that matter, in rough order of usefulness:
- Waist circumference (monthly, same spot, same time of day)
- Photos in consistent lighting (every 4 to 8 weeks)
- DEXA or body composition scan (every 12 to 26 weeks if available)
- Subjective tracking: energy, recovery, sleep quality, how clothes fit
- Lab values per your monitoring schedule
Scale weight is listed last because it belongs last. Possibly it shouldn't be on the list at all. A patient who loses 6 pounds of visceral fat and preserves 4 pounds of lean mass has had an excellent outcome, and the scale says minus 2. That number tells you almost nothing useful.
FAQ
How long until tesamorelin starts working? IGF-1 begins rising within the first week. Visible body composition changes typically develop around 12 to 16 weeks. Clinically meaningful visceral fat reduction is measurable at 26 weeks.
Should I expect changes in the first month? Mostly side effect adjustment. IGF-1 is rising, but visible body composition changes are usually not yet apparent.
Why is my weight not changing? Because visceral fat reduction is accompanied by lean mass preservation. The scale barely moves. Look at waist circumference, photos, and body composition data instead.
How long should I stay on tesamorelin? Initial protocols typically run 26 weeks (6 months) to assess response. Continued therapy maintains effects; discontinuation produces gradual regression toward baseline.
Will I see results faster at a higher dose? Doses above 2 mg are not well-studied and tend to increase side effects more than benefits. The documented optimal dose is 2 mg daily.
Does tesamorelin work without exercise? It reduces visceral fat independent of exercise, based on the trial data. But resistance training amplifies lean mass effects, and overall outcomes are better with a training stimulus.
Can I take tesamorelin with other peptides? Combination protocols exist, but each addition increases complexity and monitoring requirements. Discuss any stacking with your prescriber before starting.
---
Compounded tesamorelin is prescribed off-label for adults; the FDA-approved indication for the branded version (Egrifta) is HIV-associated lipodystrophy. Compounded tesamorelin is prepared by licensed pharmacies for individual patients based on a prescriber's clinical judgment. This article is educational only and does not constitute medical advice. Talk to a qualified clinician before starting any peptide therapy.
Related reading: Tesamorelin Visceral Fat Protocol | Tesamorelin Dosage Protocols | Tesamorelin Benefits and Research | Tesamorelin Monitoring Labs | Order Compounded Tesamorelin
---
Not FDA-approved. Compounded peptides are prepared by licensed 503A pharmacies for individual patients based on a prescriber's clinical judgment. FormBlends is not a medical practice. Individual results vary. Consult a licensed clinician before starting any peptide therapy.